Ezetimibe ameliorates cholecystosteatosis

Abhishek Mathur, Julia J. Walker, Hayder H. Al-Azzawi, Debao Lu, Deborah A. Swartz-Basile, Attila Nakeeb, Henry A. Pitt

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Cholecystosteatosis is the accumulation of gallbladder wall fats leading to decreased gallbladder emptying. Ezetimibe inhibits intestinal fat absorption and prevents murine gallstone formation. However, the influence of ezetimibe on gallbladder emptying and cholecystosteatosis has not been studied. Therefore, we tested the hypothesis that ezetimibe would improve gallbladder motility by preventing the buildup of fats in the gallbladder wall. Methods: Forty lean female mice were fed either a control diet or a lithogenic diet for 6 weeks. Half of the mice on each diet received ezetimibe. At 11 weeks of age, all mice were fasted overnight and underwent gallbladder ultrasonography to determine ejection fraction. One week later, the mice were fasted and underwent cholecystectomy. Bile was examined for cholesterol crystals. The gallbladders were snap-frozen for lipid analysis. Results: The lithogenic diet significantly (P < 0.05) increased serum cholesterol, biliary crystals, gallbladder wall cholesterol and cholesterol/phospholipid ratio, and decreased gallbladder ejection fraction. All of these abnormalities were reversed (P < 0.05) by the addition of ezetimibe to the diet. Conclusions: These data suggest that ezetimibe lowers serum cholesterol, prevents biliary crystals, and normalizes gallbladder wall fat and function. We conclude that ezetimibe ameliorates cholecystosteatosis and may be an effective agent for gallstone prevention.

Original languageEnglish
Pages (from-to)228-233
Number of pages6
JournalSurgery
Volume142
Issue number2
DOIs
StatePublished - Aug 2007

Fingerprint

Gallbladder
Cholesterol
Diet
Gallbladder Emptying
Fats
Gallstones
Ezetimibe
Intestinal Absorption
Cholecystectomy
Serum
Bile
Ultrasonography
Phospholipids
Lipids

ASJC Scopus subject areas

  • Surgery

Cite this

Mathur, A., Walker, J. J., Al-Azzawi, H. H., Lu, D., Swartz-Basile, D. A., Nakeeb, A., & Pitt, H. A. (2007). Ezetimibe ameliorates cholecystosteatosis. Surgery, 142(2), 228-233. https://doi.org/10.1016/j.surg.2007.04.007

Ezetimibe ameliorates cholecystosteatosis. / Mathur, Abhishek; Walker, Julia J.; Al-Azzawi, Hayder H.; Lu, Debao; Swartz-Basile, Deborah A.; Nakeeb, Attila; Pitt, Henry A.

In: Surgery, Vol. 142, No. 2, 08.2007, p. 228-233.

Research output: Contribution to journalArticle

Mathur, A, Walker, JJ, Al-Azzawi, HH, Lu, D, Swartz-Basile, DA, Nakeeb, A & Pitt, HA 2007, 'Ezetimibe ameliorates cholecystosteatosis', Surgery, vol. 142, no. 2, pp. 228-233. https://doi.org/10.1016/j.surg.2007.04.007
Mathur A, Walker JJ, Al-Azzawi HH, Lu D, Swartz-Basile DA, Nakeeb A et al. Ezetimibe ameliorates cholecystosteatosis. Surgery. 2007 Aug;142(2):228-233. https://doi.org/10.1016/j.surg.2007.04.007
Mathur, Abhishek ; Walker, Julia J. ; Al-Azzawi, Hayder H. ; Lu, Debao ; Swartz-Basile, Deborah A. ; Nakeeb, Attila ; Pitt, Henry A. / Ezetimibe ameliorates cholecystosteatosis. In: Surgery. 2007 ; Vol. 142, No. 2. pp. 228-233.
@article{d9c53a50aad04b26835bed6da36e9cc8,
title = "Ezetimibe ameliorates cholecystosteatosis",
abstract = "Background: Cholecystosteatosis is the accumulation of gallbladder wall fats leading to decreased gallbladder emptying. Ezetimibe inhibits intestinal fat absorption and prevents murine gallstone formation. However, the influence of ezetimibe on gallbladder emptying and cholecystosteatosis has not been studied. Therefore, we tested the hypothesis that ezetimibe would improve gallbladder motility by preventing the buildup of fats in the gallbladder wall. Methods: Forty lean female mice were fed either a control diet or a lithogenic diet for 6 weeks. Half of the mice on each diet received ezetimibe. At 11 weeks of age, all mice were fasted overnight and underwent gallbladder ultrasonography to determine ejection fraction. One week later, the mice were fasted and underwent cholecystectomy. Bile was examined for cholesterol crystals. The gallbladders were snap-frozen for lipid analysis. Results: The lithogenic diet significantly (P < 0.05) increased serum cholesterol, biliary crystals, gallbladder wall cholesterol and cholesterol/phospholipid ratio, and decreased gallbladder ejection fraction. All of these abnormalities were reversed (P < 0.05) by the addition of ezetimibe to the diet. Conclusions: These data suggest that ezetimibe lowers serum cholesterol, prevents biliary crystals, and normalizes gallbladder wall fat and function. We conclude that ezetimibe ameliorates cholecystosteatosis and may be an effective agent for gallstone prevention.",
author = "Abhishek Mathur and Walker, {Julia J.} and Al-Azzawi, {Hayder H.} and Debao Lu and Swartz-Basile, {Deborah A.} and Attila Nakeeb and Pitt, {Henry A.}",
year = "2007",
month = "8",
doi = "10.1016/j.surg.2007.04.007",
language = "English",
volume = "142",
pages = "228--233",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Ezetimibe ameliorates cholecystosteatosis

AU - Mathur, Abhishek

AU - Walker, Julia J.

AU - Al-Azzawi, Hayder H.

AU - Lu, Debao

AU - Swartz-Basile, Deborah A.

AU - Nakeeb, Attila

AU - Pitt, Henry A.

PY - 2007/8

Y1 - 2007/8

N2 - Background: Cholecystosteatosis is the accumulation of gallbladder wall fats leading to decreased gallbladder emptying. Ezetimibe inhibits intestinal fat absorption and prevents murine gallstone formation. However, the influence of ezetimibe on gallbladder emptying and cholecystosteatosis has not been studied. Therefore, we tested the hypothesis that ezetimibe would improve gallbladder motility by preventing the buildup of fats in the gallbladder wall. Methods: Forty lean female mice were fed either a control diet or a lithogenic diet for 6 weeks. Half of the mice on each diet received ezetimibe. At 11 weeks of age, all mice were fasted overnight and underwent gallbladder ultrasonography to determine ejection fraction. One week later, the mice were fasted and underwent cholecystectomy. Bile was examined for cholesterol crystals. The gallbladders were snap-frozen for lipid analysis. Results: The lithogenic diet significantly (P < 0.05) increased serum cholesterol, biliary crystals, gallbladder wall cholesterol and cholesterol/phospholipid ratio, and decreased gallbladder ejection fraction. All of these abnormalities were reversed (P < 0.05) by the addition of ezetimibe to the diet. Conclusions: These data suggest that ezetimibe lowers serum cholesterol, prevents biliary crystals, and normalizes gallbladder wall fat and function. We conclude that ezetimibe ameliorates cholecystosteatosis and may be an effective agent for gallstone prevention.

AB - Background: Cholecystosteatosis is the accumulation of gallbladder wall fats leading to decreased gallbladder emptying. Ezetimibe inhibits intestinal fat absorption and prevents murine gallstone formation. However, the influence of ezetimibe on gallbladder emptying and cholecystosteatosis has not been studied. Therefore, we tested the hypothesis that ezetimibe would improve gallbladder motility by preventing the buildup of fats in the gallbladder wall. Methods: Forty lean female mice were fed either a control diet or a lithogenic diet for 6 weeks. Half of the mice on each diet received ezetimibe. At 11 weeks of age, all mice were fasted overnight and underwent gallbladder ultrasonography to determine ejection fraction. One week later, the mice were fasted and underwent cholecystectomy. Bile was examined for cholesterol crystals. The gallbladders were snap-frozen for lipid analysis. Results: The lithogenic diet significantly (P < 0.05) increased serum cholesterol, biliary crystals, gallbladder wall cholesterol and cholesterol/phospholipid ratio, and decreased gallbladder ejection fraction. All of these abnormalities were reversed (P < 0.05) by the addition of ezetimibe to the diet. Conclusions: These data suggest that ezetimibe lowers serum cholesterol, prevents biliary crystals, and normalizes gallbladder wall fat and function. We conclude that ezetimibe ameliorates cholecystosteatosis and may be an effective agent for gallstone prevention.

UR - http://www.scopus.com/inward/record.url?scp=34547562345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547562345&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2007.04.007

DO - 10.1016/j.surg.2007.04.007

M3 - Article

VL - 142

SP - 228

EP - 233

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -